Gaede P, Diabetes Care 2008; 31(8): 1510-5
, Palmer AJ, Tucker DM, Lammert M, Parving HH, Pedersen O. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: Results and projections from the Steno-2 study.Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, Advances in Therapy 2008; 25(8): 752-74
. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.Value in Health 2008; 12(1): 1-9
, Tucker D, Palmer AJ, Minshall ME, Foos V, Silberman C. Long-Term Cost-Effectiveness of Pioglitazone versus Placebo in Addition to Existing Diabetes Treatment: A US Analysis Based on PROactive.Advances in Therapy 2008; 25(6): 567-84
, Goodall G, Aagren M, Nielsen S, Palmer AJ, Erny-Albrecht K. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes.Palmer JL, Goodall G, Nielsen S, Kotchie RW, Current Medical Research and Opinion 2008; 24(5): 1417-28
, Palmer AJ, Roze S. Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study.Ray JA, Borker R, Barber B, Value in Health 2008; 11(5): 800-8
, Belozeroff V, Palmer AJ. Cost-Effectiveness of Early versus Late Cinacalcet Treatment in Addition to Standard Care for Secondary Renal Hyperparathyroidism in the USA.Chirakup S, Chaiyakunapruk N, Chaikledkeaw U, Pongcharoensuk P, Ongphiphadhanakul B, Roze S, Value in Health 2008; 11(S1): S43-51
, Palmer AJ. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand.Goodall G, Jendle JH, International Journal of Clinical Practice 2008; 62(6): 869-76
, Munro V, Brandt AB, Ray JA, Roze S, Foos V, Palmer AJ. Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naive type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting.Minshall ME, Oglesby AK, Wintle ME, Value in Health 2008; 11(1): 22-33
, Roze S, Palmer AJ. Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus.Palmer AJ, Nephrology Dialysis Transplantation 2008; 23(4): 1216-23
, Chen R, Mehin N, Gabriel S, Bregman B, Rodby RA. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.Ali M, White J, Lee CH, Palmer JL, J Med Econ 2008; 11(4): 651-670.
, Fakhoury W, . Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia.